TAKEDA-PHARMACEUTICAL
15.2.2018 22:02:10 CET | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO: 4502 ), (“Takeda”) today announced it has become part of a select group of only thirteen (13) companies and one of two pharmaceuticals to receive global Top Employer® status for 2018. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with exceptional employee offerings. The program is organized and designed by the Institute to recognize those that create optimal conditions for their employees to develop professionally and personally, and that achieve the highest standards of excellence for their people.
To be certified globally at least 20 countries, four regions and the applicant company’s global headquarters all needed to be certified by the Top Employer Institute, which Takeda has achieved this year.
“We’d like to thank the Top Employers Institute for recognizing Takeda for the corporate culture we have created,” commented David Osborne, Takeda’s Global Human Resources Officer. “Our focus on patients, combined with our values to act with Integrity, Fairness, Honesty and Perseverance, create a dynamic environment that our people feel strongly about and in which they are empowered to shine.”
The Top Employers Institute assesses company offerings to their employees. It covers 600 HR practices across the following areas:
- Talent Strategy
- Workforce Planning
- On-boarding
- Learning & Development
- Performance Management
- Leadership Development
- Career & Succession Management
- Compensation & Benefits
- Culture
“Takeda really stands out as a global Top Employer for its commitment to people development,” said David Plink, CEO of the Top Employers Institute. “The learning opportunities provided, which enhance the employee journey and are centered on enabling employees to reach their personal professional goals, are first-class and a real differentiator.”
Takeda met the tough requirements of the Top Employers Institute, receiving accreditation in more than 20 countries and regions, across four geographic areas, namely:
- Asia Pacific: Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand
- Europe: Ireland, Russia, Spain, Turkey and Ukraine
- Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico, Peru and Venezuela
- North America: Canada and United States
- South Africa
“At Takeda, we are passionate about providing the right environment so
our people can learn and progress their careers,” said David Osborne.
“We endeavor to provide diverse learning opportunities across more than
70 countries through programs at institutions such as Oxford University,
Massachusetts Institute of Technology (MIT), Wharton and INSEAD, as well
as by establishing mentoring relationships with our most senior leaders.”
To
learn more about the Top Employers Institute and the Top Employers
certification visit http://www.top-employers.com
.
About Takeda
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas, plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/ .
Takeda’s Values & People
Takeda is building a patient-centric and customer-centric organization based on Our Values; always act upon Takeda-ism (Integrity, Fairness, Honesty and Perseverance) and do everything in the order of the four priorities of Patient-Trust-Reputation-Business . We put the patients first and foremost, and through that, we build trust with society, which solidifies our reputation, and that finally can lead to our business performance. These are deeply ingrained in our ways of working. They ensure our commitment to quality and that we do the right thing - at all times.
Our local organizations and people are empowered to respond in the best way to customer needs, and have the possibility to develop and thrive in a diverse and agile organization.
Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future.
Takeda: Empowering Our People to Shine
Working at Takeda, it is important that our people feel empowered to perform to the very best of their ability as they work towards creating a brighter future for millions of patients worldwide. We enable all our people to grow, providing support and training where needed, and fostering a culture of trust to allow leadership at all levels.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005439/en/
Contact:
Media contacts
Media outside Japan:
Takeda
Pharmaceutical Company Limited
Vince Docherty, +65 8332 4233
vince.docherty@takeda.com
Takeda
Pharmaceutical Company Limited
Rebecca Northridge, +65 9457 6037
rebecca.northridge@takeda.com
Japanese
Media:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi,
+81 3 3278 2095
kazumi.kobayashi@takeda.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
